Enfusion - ENFN Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ENFN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENFN, but not buy additional shares or sell existing shares.
View ENFN analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12-month target prices for Enfusion's shares. Their ENFN share price forecasts range from $9.50 to $14.00. On average, they expect the company's share price to reach $11.58 in the next twelve months. This suggests a possible upside of 10.4% from the stock's current price.
View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts.

Enfusion's stock was trading at $9.67 on January 1st, 2023. Since then, ENFN stock has increased by 8.5% and is now trading at $10.49.
View the best growth stocks for 2023 here.

Enfusion saw a drop in short interest in February. As of February 15th, there was short interest totaling 1,810,000 shares, a drop of 18.5% from the January 31st total of 2,220,000 shares. Based on an average daily volume of 372,900 shares, the short-interest ratio is presently 4.9 days. Currently, 7.1% of the company's stock are sold short.
View Enfusion's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our ENFN earnings forecast.

Enfusion, Inc. (NYSE:ENFN) announced its earnings results on Tuesday, March, 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The business earned $40.52 million during the quarter, compared to the consensus estimate of $39.88 million. Enfusion had a negative net margin of 4.90% and a positive trailing twelve-month return on equity of 3.80%.

ETFs with the largest weight of Enfusion (NYSE:ENFN) stock in their portfolio include Direxion Daily Cloud Computing Bull 2x (CLDL).Ranger Equity Bear ETF (HDGE).

Enfusion issued an update on its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $185.00 million-$190.00 million, compared to the consensus revenue estimate of $188.13 million.

(ENFN) raised $300 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.

Enfusion trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENFN."

Enfusion's stock is owned by a variety of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (0.95%), New York State Common Retirement Fund (0.59%), Geode Capital Management LLC (0.31%), Bank of America Corp DE (0.17%), Franchise Capital Ltd (0.17%) and Charles Schwab Investment Management Inc. (0.12%). Insiders that own company stock include Dan Groman, Hillhouse Investment Managemen, Roy Luo, Stephen Malherbe and Tarek Hammoud.
View institutional ownership trends.

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENFN stock can currently be purchased for approximately $10.49.

Enfusion (NYSE:ENFN) has a market capitalization of $1.21 billion and generates $150.35 million in revenue each year. The company earns $-7,650,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

The company employs 1,006 workers across the globe.

The official website for the company is www.enfusion.com. The company can be reached via phone at 312-253-9800 or via email at brian.murphy@icrinc.com.